Factors associated with advanced-stage diagnosis of cervical cancer in Estonia: a population-based study

Abstract

ObjectivesCervical cancer (CC) remains a crucial public health issue in Estonia, with high incidence and late diagnosis. The aim of this study was to examine time trends of stage-specific CC incidence in Estonia and factors associated with advanced-stage diagnosis of CC. Study designThis was a nationwide population-based retrospective study. MethodsData on CC cases diagnosed in Estonia in 2007–2018 were obtained from the Estonian Cancer Registry, including tumour, nodes, metastases stage at diagnosis. Sociodemographic data were obtained from the Population Registry. To estimate the risk of advanced-stage diagnosis (stages II–IV vs stage I) associated with sociodemographic factors, Poisson regression with robust variance was used to calculate univariate and multivariate prevalence ratios (PR) with 95% confidence intervals (CIs). Time trends of stage-specific CC incidence for 2005–2019 were examined with joinpoint analysis. ResultsIncidence of stage I CC showed a significant decline of 4.9% per year since 2007, whereas no change was seen for other stages. Of the 2046 women diagnosed in 2007–2018, 1137 (55.6%) were diagnosed at an advanced stage; this proportion increased from 51% in 2007–2009 to 58% in 2015–2018 (P = 0.004). Multivariate regression analysis showed that advanced-stage diagnosis was associated with age (PR 2.16, 95% CI 1.87–2.49 for women aged ≥75 years compared with those aged 30–44 years), educational level (PR 1.32, 95% CI 1.15–1.51 for women with basic/primary education compared to university education) and marital status (PR 1.14, 95% CI 1.01–1.29 for single women compared to married/cohabiting women). No associations were observed by region of residence or nationality. ConclusionsTo reduce CC mortality, it is crucial to improve prevention and early diagnosis of CC in Estonia through human papillomavirus vaccination and effective and quality-assured screening particularly targeting high-risk groups as well as encouraging symptom awareness and regular check-ups among older women.